Doximity growth slows to 13% as pharma budget caution hits bookings; net income falls 12%

Filed May 19, 2026 · Period ending March 31, 2026 · Compared to 10-K May 20, 2025 · ~2 min read

Key Changes

• high

  Revenue growth decelerated from 20% to 13% YoY; net income declined 12% to $196M despite higher revenue, driven by 40% R&D expense surge and 43% G&A increase (legal fees, stock comp).

  MD&A: Financial Results verify on EDGAR →
• high

  Federal pricing policy uncertainty (Most Favored Nation negotiations) caused pharma customer budget caution and affected Marketing Solutions bookings timing in FY2026; company cannot quantify future impact.

  Risk Factors: Customer Demand verify on EDGAR →
• high

  Launched Clinical AI Suite (Ask, Scribe, Prescribe) with 140+ health systems adopting after governance review; registered members grew to 3M+ (85%+ of U.S. physicians); named Abridge, OpenAI, Anthropic as AI competitors.

  Business: Product Expansion verify on EDGAR →